SystemicTx is pleased to announce the appointment of its executive team, characterized by deep experience and proven track records of building and scaling businesses and drug developments across a variety of industries.
Hamilton, Ontario--(Newsfile Corp. - January 31, 2022) - Systemic Therapeutics Corp. (the “Company” or “SystemicTx”) is a pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulators of lipid metabolism, the sterol regulatory-element binding proteins (SREBP), based on first-in-class SREBP inhibitors. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as dyslipidemia and Non-Alcoholic Steatohepatitis (NASH).
SystemicTx is pleased to announce the appointment of its executive team, characterized by deep experience and proven track records of building and scaling businesses and drug developments across a variety of industries. The SystemicTx team includes physicians, scientists, geneticists, entrepreneurs, drug discovery and intellectual property experts.
“We are tremendously excited about this opportunity to bring together world class experts in human genetics, molecular and cellular biology and medicinal chemistry into one team with the sole purpose of developing the next generation of medicines for the treatment of cardiometabolic diseases and their vascular complications,” commented Richard Austin, Co-Founder, Executive Chairman and Chief Scientific Officer.
The SystemicTx executive team consists of the following:
Richard Austin, BSc MSc PhD
Executive Chairman and Chief Scientific Officer
Dr. Austin is the Co-Founder, Executive Chairman and Chief Scientific Officer of SystemicTx. He received his PhD in Medical Sciences from McMaster University. He also trained as a Postdoctoral Fellow in the Department of Human Genetics, Hospital for Sick Children in Toronto. Dr. Austin is currently a Professor of Medicine in the Division of Nephrology, McMaster University and St. Joseph’s Healthcare Hamilton. He is also a Career Investigator of the Heart and Stroke Foundation of Ontario (HSFO) and holds the Amgen Canada Research Chair in Nephrology. Dr. Austin’s research focuses on the role of PCSK9 as well as the cellular stress pathways that drive cardiometabolic disease. He has published over 160 articles, reviews and book chapters in peer-reviewed journals, with over 10,500 citations and an h-index of 51. Dr. Austin has given over 100 lectures in >15 countries as well as contributing to numerous national and international granting agencies and biopharmaceutical companies.
Fady Hannah-Shmouni, MD DABIM FRCPC
Chief Executive Officer
Dr. Hannah-Shmouni is the Co-Founder and Chief Executive Officer of SystemicTx, and a physician-scientist in neuroendocrinology, metabolism and genetics. Prior to joining SystemicTx, Dr. Hannah-Shmouni has held various leadership roles, in public and private companies. He completed clinical training in internal medicine at Yale School of Medicine; adult endocrinology, diabetes and metabolism at the National Institutes of Health, America’s research hospital; and clinical biochemical genetics at the University of Toronto. He is board-certified in internal medicine and endocrinology by the American Board of Internal Medicine and Royal College of Physician and Surgeons of Canada; and in clinical hypertension by American Society of Hypertension. Dr. Hannah-Shmouni’s research focuses on the evaluation and treatment of inborn errors of metabolism and adrenal disorders. He has published over 100 articles, reviews and book chapters in peer-reviewed journals and is the Editor-In-Chief of Endocrine and Metabolic Science (Elsevier). Dr. Hannah-Shmouni co-founded FalconView Venture Capital (California, USA), specialising in early-stage startup consultations and investments. He is a board advisor for Exerkine (exerkine.com), a biotechnology company developing novel therapies for the treatment of genetic and aging-associated diseases, and IPEX (ipex.network), world’s first company to unlock the real value of an organisation’s intangible assets through blockchain technology.
Mark Tarnopolsky, MD PhD FRCPC
Vice President, Business Development
Dr. Tarnopolsky is the Co-Founder and Vice President of Business Development at SystemicTx. He received an MD and PhD (Cell Biology and Metabolism) from McMaster University. He is a clinician-scientist with an endowed chair from McMaster Children’s Hospital Foundation in the area of neuromuscular and neurometabolic genetic disorders. His research focuses on nutraceutical and exercise therapies for neurometabolic disorders, aging, obesity and other disorders that affect the mitochondria. He has published on the neuromuscular effects of caffeine over 20 years. He was the co-founder and CSO of Life Science Nutritionals and is the founder, CEO and CSO of Exerkine Corporation and CSO for Cora Therapeutics. Dr. Tarnopolsky’s research focuses on the evaluation of treatment strategies to attenuate the effect of neuromuscular disorders and aging on skeletal muscle function. He has published over 500 articles in peer-reviewed journals, and is highly regarded as an authority on the science of exercise.
Guillaume Paré, MD MSc FRCPC
Chief Medical Officer
Dr. Paré is The Co-Founder and Chief Medical Officer of SystemicTx. He received his MD from University of Montreal and a Master’s in Human Genetics at McGill University under the supervision of renowned geneticist Dr. Thomas Hudson. He further trained as a post-doctoral fellow under the guidance of Dr. Paul Ridker at Harvard Medical School. He is a University Scholar and Professor of Pathology and Molecular Medicine at McMaster University, Director of the Genetic and Molecular Epidemiology Laboratory, Deputy Director of the Thrombosis and Atherosclerosis Research Institute, and Senior Scientist at the Population Health Research Institute. Dr. Paré’s research focuses on the genetic and molecular epidemiology of cardio-metabolic diseases. He has published over 250 articles in peer-reviewed journals, cited over 35,000 times. Dr. Paré has given over 200 lectures in over 25 countries and is regularly invited to global and national Scientific Advisory Boards by leading pharmaceutical and biotechnology companies.
Jakob Magolan, PhD
Vice President, Drug Discovery
Dr. Magolan is the Co-Founder and Vice President of Drug Discovery at SystemicTx. He is an Associate Professor at McMaster University where he holds the Boris Family Endowed Chair in Drug Discovery. An expert organic and medicinal chemist, Dr. Magolan runs a research laboratory with extensive synthetic chemistry capacity. His program routinely pursues clinically-relevant medicinal chemistry initiatives with the aim of discovery and development of new medicines. Dr. Magolan completed undergraduate studies at Queen’s University and received a PhD from Western University. He conducted postdoctoral research at the Griffith University Institute for Drug Discovery in Australia and then began his independent career in the Department of Chemistry at University of Idaho where he worked for seven years and earned tenure prior to being recruited to McMaster in 2017. He has published more than thirty articles in peer-reviewed journals (h index 15). Dr. Magolan’s laboratory space at McMaster will host SystemicTx’s chemistry team and he will direct the company’s medicinal chemistry development program.
About Systemic Therapeutics Corp.
Systemic Therapeutics Corp. is a Canadian pre-clinical stage, biotechnology company specialized in the development of new therapies focusing on the master regulator of lipid metabolism, sterol regulatory-element binding proteins (SREBP), based on first-in-class SREBP inhibitors. The Company aims to provide new treatment options for metabolic conditions such as dyslipidemia and Non-Alcoholic Steatohepatitis (NASH). www.SystemicTx.com
Corporate Communications :
Fady Hannah-Shmouni, MD DABIM FRCPC
Co-Founder and Chief Executive Officer
Systemic Therapeutics Corp.
Tel: (647) 647-3816
Email: fady@systemictx.com
Website: www.SystemicTx.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112223
